| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
|
Clin Cancer Res
|
2008
|
1.47
|
|
2
|
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
|
Blood
|
2009
|
1.42
|
|
3
|
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
|
J Clin Oncol
|
2010
|
1.33
|
|
4
|
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
|
PLoS One
|
2010
|
1.29
|
|
5
|
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
|
Cancer Chemother Pharmacol
|
2009
|
1.08
|
|
6
|
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
|
Cancer Chemother Pharmacol
|
2010
|
1.03
|
|
7
|
Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.
|
Drug Metab Dispos
|
2005
|
0.93
|
|
8
|
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
|
Br J Haematol
|
2014
|
0.93
|
|
9
|
Characterization of humanized antibodies secreted by Aspergillus niger.
|
Appl Environ Microbiol
|
2004
|
0.91
|
|
10
|
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
|
Clin Cancer Res
|
2010
|
0.91
|
|
11
|
Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
|
Bioconjug Chem
|
2006
|
0.88
|
|
12
|
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.
|
Dalton Trans
|
2015
|
0.88
|
|
13
|
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
|
Oncogene
|
2002
|
0.86
|
|
14
|
Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
|
BioDrugs
|
2002
|
0.81
|